With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
|Articles|September 1, 2022
Take the Direct Route to Commercialization in Canada
Author(s)Innomar Strategies
Advertisement
In addition to being among the top 10 pharmaceutical markets in the world, Sandra Anderson, Senior Vice President, Commercialization and Strategy, discusses why the Canadian pharmaceutical sector has a growing presence and what makes it so attractive to manufacturers.
Not only does Innomar Strategies provide strategic advice and planning, but we also execute and implement all end-to-end commercialization services for companies launching a new therapy into the Canadian marketplace.
Advertisement
Related to this article
As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.
Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
FAQ: What Comes Next for the 340B Rebate Pilot
2
How Early Development Decisions Shape Commercial Readiness for Biologics
3
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
4
Copeland Closes Dickson Deal to Expand Cold Chain Monitoring
5